Details for Patent: 8,580,858
✉ Email this page to a colleague
Which drugs does patent 8,580,858 protect, and when does it expire?
Patent 8,580,858 protects NAMZARIC and is included in one NDA.
This patent has fifty-seven patent family members in eighteen countries.
Summary for Patent: 8,580,858
| Title: | Compositions for the treatment of CNS-related conditions |
| Abstract: | The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration. |
| Inventor(s): | Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, CA) |
| Assignee: | Adamas Pharmaceuticals, Inc. (Emeryville, CA) |
| Application Number: | 13/725,246 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,580,858 |
|
Patent Claim Types: see list of patent claims | Use; Dosage form; Composition; |
Drugs Protected by US Patent 8,580,858
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-003 | Jul 18, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Try a Trial | ||||
| Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-001 | Dec 23, 2014 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Try a Trial | ||||
| Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-004 | Jul 18, 2016 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Try a Trial | |||
| Abbvie | NAMZARIC | donepezil hydrochloride; memantine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 206439-002 | Dec 23, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,580,858
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E481096 | ⤷ Try a Trial | |||
| Australia | 2005209310 | ⤷ Try a Trial | |||
| Australia | 2005215767 | ⤷ Try a Trial | |||
| Australia | 2005215775 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
